Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Biogen Inc BIIB

Healthcare Drug Manufacturers - Major
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating... see more

Current News (NDAQ:BIIB)

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

GlobeNewswire 4 days ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Business Wire 4 days ago

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

PR Newswire 6 days ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

PR Newswire 7 days ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Business Wire 8 days ago

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

PR Newswire November 25, 2025

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

GlobeNewswire November 24, 2025

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference

GlobeNewswire November 20, 2025

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

GlobeNewswire November 17, 2025
View More News ››

Opinion & Analysis (NDAQ:BIIB)

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Streetwise Reports October 23, 2019

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Streetwise Reports March 7, 2019

Potential Alzheimer's therapies focus on early intervention

Streetwise Reports December 1, 2017

Big biotech's value is bolstered by focus on Alzheimer's disease

The Life Sciences Report November 1, 2017

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017
View More Opinion ››

Bullboard Posts (NDAQ:BIIB)

Looks like a bargain to me.

I'm not skilled at Technical Analysis, but this looks like a good entry point. I'm in. VP in AZ
ValuePro - February 24, 2025

Biogen (NASDAQ:BIIB) – A Diversified Powerhouse Naviga

http://beyondspx.com/2024/07/31/biogen-nasdaqbiib-a-diversified-powerhouse-navigating-the-evolving-pharmaceutical-landscape/
MikeTester - August 2, 2024

Lignans Market Trends, Demand, Share and Reports 2021-2026

According to IMARC Group’s latest report, titled “Lignans Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast...
edwardebreen15 - August 9, 2022

RE:Biogen Sees Two Long-Time Directors Announce Retirement

A little fresh blood in management is good.
Joe455 - May 29, 2022

Biogen Sees Two Long-Time Directors Announce Retirement

Biogen Inc appears to be facing issues related to its executive team. The firm this morning indicated that two long time directors of...
AwareInvestor - January 31, 2022

Outrageous that this was ever approved.

They fail to mention the brain lesions, edema, and bleeding that this drug causes.  They fail to mention that the average AD...
TinToronto - June 12, 2021
View more Bullboard ››

BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms ...
View More »